ArticleCurrent treatment options in rheumatology2021
Insights Into Systemic Sclerosis from Gene Expression Profiling.
Article in Current treatment options in rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Purpose of review: The emergence of genomic data science stands poised to revolutionize our molecular understanding of the heterogeneity of complex diseases including systemic autoimmune diseases. In systemic sclerosis (SSc), bulk and single-cell transcriptomics have provided a new lens into the heterogeneity of this complex condition, both in terms of molecular heterogeneity, treatment response, and cell types important for the disease. Recent findings: Transcriptomics has revealed reproducible patterns of gene expression among SSc patients. These conserved patterns of gene expression provide insights into SSc etiology, and evidence suggests that these groups may have important implications for treatment decisions by targeting specific patients. Integration and analyses of publicly available data are providing new insights into the disease. Single-cell technologies are illuminating cell types that may be important in pathogenesis. The disease trajectory for SSc remains difficult to predict, but the interactions between adaptive and innate immune cells with tissue-resident stromal cells may play an important role. Summary: The heterogeneity in SSc can be broken down and quantified using molecular methods that range from bulk analysis to single cells. Further study of cellular and molecular dynamics in end-target tissues is likely to result in better disease management through personalized, data-driven treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.